Abstract: PL 93–642 authorizes the Foundation to provide for the conduct of a national competition for the purpose of selecting Truman scholars. The purpose of this information collection through the NIF is to enable a committee to review the credentials of applicants and to determine which appear to meet the selection criteria and should be designated as Finalists and invited to an interview. For persons invited to the interview, the information collection through the NIF helps the Truman Scholars Selection Panel make its decisions after interviewing the Finalists. Data collected include: schools attended; campus, community and government activities and services; awards received; leadership and public service interests and ambitions; graduate study plans; and other information that candidates deem significant. It also includes a 700–800-word analysis of a public policy issue chosen by the applicant to demonstrate analytical and writing skills. The data are used only by Foundation staff or selection committees except for items that may be used to publicize the program, to provide examples to help candidates in future years, or aggregated for educational research purposes.

Likely respondents: The likely respondents consist of 800–900 college juniors who wish to receive support from the Foundation to attend graduate school in preparation for careers in the public service. Each applicant is required to submit this application only once. He/she is also required to provide four letters of recommendation including one from the Truman Scholarship Faculty Representative at his/her institution:

Burden Statement: The current total annual respondent burden is estimated at 20,000 hours based on 800 applicants spending 25 hours each on the application and the public policy analysis.

II. Frequency of Collection

Annual.

III. Public Docket

A public version of this record, including printed, paper versions of electronic comments is available for inspection from 8:00 a.m. to 5:00 p.m., Monday through Thursday, excluding legal holidays. The public record is located at 712 Jackson Place, NW, third floor, Washington, DC 20006.

Dated: October 10, 1996.

Louis H. Blair,

Executive Secretary, Harry S. Truman Scholarship Foundation.

[FR Doc. 96–26427 Filed 10–15–96; 8:45 am]

BILLING CODE 6820–AP–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; Comment Request; Contraception and Infertility Research Loan Repayment Program (CIR–LRP)

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Institute of Child Health and Human Development, (NICHD), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information on collection listed below. This proposed information collection was previously in the Federal Register on September 21, 1995, page 49000 and allowed 60 days for public comment. No public comments were received. The purposes of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: *Title:* Contraception and Infertility Research Loan Repayment Program. *Type of Information Collection Request:* NEW. *Need and Use of Information Collection:* The information proposed for collection will be used by NICHD to determine an applicant's eligibility for participation in the CIR–LRP. It will enable the NICHD to select qualified individuals for participation in the program, and to deliver eligible benefits.

The annual burden estimates are as follows:

TABLE

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Applicants	50	1	5.5	275
Lender	200	1	0.5	100
State/Other Entity	8	1	0.5	4

The annualized cost to respondents is estimated at $8,460. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUESTS FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden to the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

DIRECT COMMENTS TO OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Louis V. DePaolo, Ph.D., Reproductive Sciences Branch, Center for Population Research, NICHD, NIH, Building 61E, Room 8B01, Bethesda, Maryland 20892–7510.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within on or before November 15, 1996.

Dated: October 9, 1996.

Benjamin E. Fulton,

Executive Officer, NICHD.

[FR Doc. 96–26412 Filed 10–15–96; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting George H. Keller, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7735 ext 246; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

A Method of Detecting Transmissible Spongiform Encephalopathies

G. Hsich, C.J. Gibbs, K. Kenney, M.G. Harrington (NINDS)
Filed 5 Apr 96
DHHS Reference No. E–055–96/0

Improved assays for the detection of transmissible spongiform encephalopathies (TSEs) in humans and non-human mammals have been developed. The assays involve detecting the presence or absence of 14–3–3 proteins in cerebrospinal fluid. Elevated levels of these proteins are indicative of TSEs, in particular Creutzfeldt-Jacob disease in humans and animals with these diseases. This invention is available for licensing on a non-exclusive basis.

Dated: October 2, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–26410 Filed 10–15–96; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent applications referenced below may be obtained by contacting Larry Tiffany, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7056 ext 206; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

Recombinant Pseudomonas Exotoxin With Increased Activity

IH Pastan, DJ Fitzgerald (NCI)
Serial Nos. 07/901,709 filed 18 Jun 92 and 08/405,615 filed 15 Mar 95 (FWC of 07/901,709); also 08/463,480 and 08/461,234 filed on 05 Jun 95 (DIVs of 08/405,615)

Development of novel recombinant *Pseudomonas* exotoxin molecules with higher target cell toxicity and less nonspecific cell toxicity offers to significantly improve the effectiveness of immunotherapies against virally infected and cancer cells. Toxins attached to growth factors, antibodies, and other cell-targeting molecules can be used to kill harmful cells bearing specific surface receptors or antigens. One promising source of an effective therapeutic toxin is *Pseudomonas* exotoxin (PE) A, an extremely active monomeric protein that is excreted by the bacteria Pseudomonas aeruginosa. PE, which causes cell death by inhibiting protein synthesis in eukaryotic cells, contains three structural domains that act in concert to cause cytotoxicity: domain Ia mediates cell binding, domain II is responsible for translocation into the cytosol, and domain III leads indirectly to inhibition of protein synthesis. Unfortunately, immunotoxins made with native PE also attack the liver and—when given in large doses—may produce death due to liver toxicity. This problem has been overcome by cleaving parts of the native endotoxin molecule including all of domain Ia and part of domain II. Such ''pre-cleaved'' PE molecules are smaller in size and, thus, less likely to be immunogenic. They also are better able to penetrate tumors. These new PE molecules are at least 20 times more cytotoxic to target cells and less cytotoxic to normal cells than previously developed PE immunotoxins.

Dated: October 2, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–26411 Filed 10–15–96; 8:45 am]

BILLING CODE 4140–01–M

National Center for Research Resources; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: Board of Scientific Counselors, National Center for Research Resources (NCRR).

Dates of Meeting: November 18–19, 1996.

Time: 8:00 a.m.-until adjournment.

Place of Meeting: National Institutes of Health, 9000 Rockville Pike, Conference Room G, Building 45, Bethesda, Maryland 20892.

Scientific Review Administrator: Dr. Louise Ramm, Deputy Director, National Center for Research Resources, Building 12A, Room 4011, Bethesda, MD 20892, Telephone: (301) 496–6023.

Purpose/Agenda: For the review of the NCRR intramural research program.

In accordance with the provisions set forth in section 552(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92–463, the meeting will be closed to the public for the review, discussion and evaluation of individual programs and projects conducted by the National Institutes of Health, including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dated: October 8, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96–26409 Filed 10–15–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Meeting: Board of Scientific Counselors

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Board of Scientific Counselors,